- Home
- TARS vs CSAN Comparison
TARS vs CSAN Comparison
Compare TARS & CSAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TARS | CSAN |
|---|---|---|
| Founded | 2016 | 1936 |
| Country | United States | Brazil |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Retail-Auto Dealers and Gas Stations |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 3.0B |
| IPO Year | 2020 | 2008 |
Fundamental Metrics
Financial Performance| Metric | TARS | CSAN |
|---|---|---|
| Price | $58.46 | $3.01 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 6 | 2 |
| Target Price | ★ $89.00 | $4.75 |
| AVG Volume (30 Days) | ★ 1.4M | 995.8K |
| Earning Date | 05-06-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 48.21 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $451,360,000.00 | N/A |
| Revenue This Year | $56.43 | $321.51 |
| Revenue Next Year | $30.19 | $3.57 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 146.71 | N/A |
| 52 Week Low | $38.51 | $2.52 |
| 52 Week High | $85.25 | $6.01 |
Technical Indicators
Market Signals| Indicator | TARS | CSAN |
|---|---|---|
| Relative Strength Index (RSI) | 45.13 | 49.46 |
| Support Level | $56.05 | $2.71 |
| Resistance Level | $67.14 | $3.19 |
| Average True Range (ATR) | 3.54 | 0.09 |
| MACD | -0.35 | 0.02 |
| Stochastic Oscillator | 23.72 | 31.38 |
Price Performance
Historical ComparisonAbout TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.
About CSAN Cosan S.A. ADS
Cosan SA engages in several services throughout the energy and logistics sectors. Its reportable segments are Raizen, Compass, Moove, Rumo, and Radar. It generates the majority of its revenue from Raizen which operates in the production, commercialization, origination, and trading of ethanol, bioenergy, resale, and trading of electricity, renewable sources, marketing, origination, and trading of sugar and fuels, and lubricant.